Acadia stock rallies on drug news as Roivant also climbs, while Leslie's, Theseus shares plunge and more moving stocksMarket Watch • 07/14/23
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X SyndromeBusiness Wire • 07/13/23
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi SyndromeBusiness Wire • 06/13/23
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett SyndromeBusiness Wire • 06/08/23
Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/07/23
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceBusiness Wire • 06/01/23
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 05/25/23
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/23
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating OverviewBusiness Wire • 05/08/23
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023Business Wire • 04/25/23
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual MeetingBusiness Wire • 04/20/23
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett SyndromeBusiness Wire • 04/17/23
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/11/23
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's TypeBusiness Wire • 04/03/23